October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Paolo Tarantino: HER2: a remarkable story of precision oncology
Jul 23, 2024, 08:25

Paolo Tarantino: HER2: a remarkable story of precision oncology

Paolo Tarantino shared on X:

HER2: a remarkable story of precision oncology.

Check this wonderful Nature review on targeting HER2 beyond breast. Important to remember: now that we have an agnostic anti-HER2 drug approved (T-DXd), every adv cancer patient should get HER2 testing!

HER2-targeted therapies beyond breast cancer — an update

Authors: Jeesun Yoon, Do-Youn Oh.

Paolo Tarantino

Paolo Tarantino

Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.

With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.